Publications
192
Citations
2,056
Est. group size
—
Recurring co-author estimate
Active years
28
Publishing since 1999
Enrico Caserta's work centers on targeted radionuclide therapy for blood cancers, using mathematical modeling to study how radiation-based treatments can be optimized. This involves combining approaches from radiopharmaceutical chemistry, cancer biology, and quantitative modeling of tumor growth and radiation effects. The listed recent items are supplementary figures from a single large modeling study, suggesting this is a detailed, multi-part research output rather than many distinct standalone papers.
Publication output was relatively steady and modest from 2017 through 2022, then increased sharply starting in 2023 and remained high through 2024-2026, though much of this recent volume reflects supplementary components of a single major study rather than distinct papers.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Supplementary Figure S.12 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.31 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.14 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.29 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.32 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.3 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.10 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.11 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.7 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.22 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.30 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.21 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.28 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.24 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Supplementary Figure S.13 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2026
- Blood×17
- JCI Insight×3
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Clinical Lymphoma Myeloma & Leukemia×3
- Cancer Research×3
- Jyoti Roy
Medicine · Purdue University West Lafayette
- Shuang Liu
Medicine · Purdue University West Lafayette
- George H. Hinkle
Medicine · The Ohio State University
- Edward W. Martin
Medicine · The Ohio State University
- Kai Chen
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile